Influence of dietary supplementation of short-chain fatty acid sodium propionate in people living with HIV (PLHIV).
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
08
12
2021
received:
18
07
2021
accepted:
07
01
2022
pubmed:
18
2
2022
medline:
14
5
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Non-AIDS-associated chronic diseases in HIV+ patients have been on the rise since the advent of antiretroviral therapy. Especially cardiovascular diseases and disruption in the gastrointestinal tract have limited health-related quality of life (QoL). Several of those complications have been associated with chronic systemic inflammation. Short-chain fatty acids (SCFA), with propionate as one of the major compounds, have been described as an important link between gut microbiota and the immune system, defining the pro- and the anti-inflammatory milieu through direct and indirect regulation of T-cell homeostasis. The effects of dietary supplementation of sodium propionate (SP) in people living with HIV (PLHIV) have not yet been investigated prior to this study. To investigate the impact of SP uptake among PLHIV and its relevance to improve QoL, the study aimed to investigate metabolic, immunological, microbiome and patient-reported QoL-related changes post-SP supplementation with follow-up. A prospective, non-randomized, controlled, monocentric interventional study was conducted in WIR, Center for Sexual Health and Medicine, in Bochum, Germany. 32 HIV+ patients with unaltered ART-regimen in the last three months were included. Participants were given SP for a duration of 12 weeks in the form of daily oral supplementation and were additionally followed-up for another 12 weeks. The supplementation of SP was well tolerated. We found an improvement in lipid profiles and long-term blood glucose levels. A decrease in pro-inflammatory cytokines and a depletion of effector T cells was observed. Regulatory T cells and IL-10 decreased. Furthermore, changes in taxonomic composition of the microbiome during follow-up were observed and improvement of items of self-reported life-quality assessment. Taken together, the beneficial impact of SP in PLHIV reflects its potential in improving metabolic parameters and modulating pro-inflammatory immune responses. Thus, possibly reducing the risk of cardiovascular disorders and facilitating long-term improvement of the gut flora.
Sections du résumé
BACKGROUND
BACKGROUND
Non-AIDS-associated chronic diseases in HIV+ patients have been on the rise since the advent of antiretroviral therapy. Especially cardiovascular diseases and disruption in the gastrointestinal tract have limited health-related quality of life (QoL). Several of those complications have been associated with chronic systemic inflammation. Short-chain fatty acids (SCFA), with propionate as one of the major compounds, have been described as an important link between gut microbiota and the immune system, defining the pro- and the anti-inflammatory milieu through direct and indirect regulation of T-cell homeostasis. The effects of dietary supplementation of sodium propionate (SP) in people living with HIV (PLHIV) have not yet been investigated prior to this study.
OBJECTIVES
OBJECTIVE
To investigate the impact of SP uptake among PLHIV and its relevance to improve QoL, the study aimed to investigate metabolic, immunological, microbiome and patient-reported QoL-related changes post-SP supplementation with follow-up.
METHODS
METHODS
A prospective, non-randomized, controlled, monocentric interventional study was conducted in WIR, Center for Sexual Health and Medicine, in Bochum, Germany. 32 HIV+ patients with unaltered ART-regimen in the last three months were included. Participants were given SP for a duration of 12 weeks in the form of daily oral supplementation and were additionally followed-up for another 12 weeks.
RESULTS
RESULTS
The supplementation of SP was well tolerated. We found an improvement in lipid profiles and long-term blood glucose levels. A decrease in pro-inflammatory cytokines and a depletion of effector T cells was observed. Regulatory T cells and IL-10 decreased. Furthermore, changes in taxonomic composition of the microbiome during follow-up were observed and improvement of items of self-reported life-quality assessment.
CONCLUSION
CONCLUSIONS
Taken together, the beneficial impact of SP in PLHIV reflects its potential in improving metabolic parameters and modulating pro-inflammatory immune responses. Thus, possibly reducing the risk of cardiovascular disorders and facilitating long-term improvement of the gut flora.
Substances chimiques
Fatty Acids, Volatile
0
Propionates
0
sodium propionate
DK6Y9P42IN
Types de publication
Clinical Trial
Controlled Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
881-889Subventions
Organisme : Flexopharm Brain GmbH & Co. KG
Informations de copyright
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382: 1525-1533.
Nordell AD, McKenna M, Borges AH et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3: 1-10.
Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39: 633-645.
Siddiqui U, Bini EJ, Chandarana K et al. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol 2007; 41: 484-490.
Wilcox CM, Saag MS. Gastrointestinal complications of HIV infection: changing priorities in the HAART era. Gut 2008; 57: 861-870.
MacArthur RD. Management of noninfectious diarrhea associated with HIV and highly active antiretroviral therapy. Am J Manag Care 2013; 19: 238-248.
Saravolatz LD, MacArthur RD, Dupont HL. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis 2012; 55: 860-867.
Feasey NA, Healey P, Gordon MA. Review article: the aetiology, investigation and management of diarrhoea in the HIV-positive patient. Aliment Pharmacol Ther 2011; 34: 587-603.
Vinolo MAR, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients 2011; 3: 858-876.
Puddu A, Sanguineti R, Montecucco F, Viviani GL. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediators Inflamm 2014; 2014.
Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MAR. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol 2016; 5: 1-8.
Cox MA, Jackson J, Stanton M et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E2 and cytokines. World J Gastroenterol 2009; 15: 5549-5557.
Trompette A, Gollwitzer ES, Yadava K et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014; 20: 159-166.
Haghikia A, Jörg S, Duscha A et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity 2015; 43: 817-829.
Duscha A, Gisevius B, Hirschberg S et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell 2020; 180: 1067-1080.e16.
Hegelmaier T, Lebbing M, Duscha A et al. Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson’s disease. Cells 2020; 9: 376.
Bartolomaeus H, Balogh A, Yakoub M et al. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation 2019; 139: 1407-1421.
Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007; 13: 2826-2832.
Maslowski KM, Vieira AT, Ng A et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461: 1282-1286.
Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 2015; 11: 577-591.
Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients 2015; 7: 2839-2849.
Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol 2014; 121: 91-119.
Smith PM, Howitt MR, Panikov N et al. The microbial metabolites, short-chain fatty acids, regulate colonic T reg cell homeostasis. Science 2013; 341: 569-573.
Hirschberg S, Gisevius B, Duscha A, Haghikia A. Implications of diet and the gut microbiome in neuroinflammatory and neurodegenerative diseases. Int J Mol Sci 2019; 20: 3109.
Haase S, Haghikia A, Wilck N, Müller DN, Linker RA. Impacts of microbiome metabolites on immune regulation and autoimmunity. Immunology 2018; 154: 230-238.
Haase S, Haghikia A, Gold R, Linker RA. Dietary fatty acids and susceptibility to multiple sclerosis. Mult. Scler 2018; 24: 12-16.
Gurav A, Sivaprakasam S, Bhutia YD et al. Slc5a8, a Na+-coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour suppressor in colon that protects against colitis and colon cancer under low-fibre dietary conditions. Biochem J 2015; 469: 267-278.
Park J, Kim M, Jannasch AH et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol 2015; 8: 80-93.
Kim CH, Park J, Kim M. Gut microbiota-derived short-chain Fatty acids, T cells, and inflammation. Immune Netw 2014; 14: 277-288.
Arpaia N, Campbell C, Fan X et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-455.
Li M, van Esch BCAM, Wagenaar GTM et al. Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur J Pharmacol 2018; 831: 52-59.
Iraporda C, Errea A, Romanin DE et al. Lactate and short chain fatty acids produced by microbial fermentation downregulate proinflammatory responses in intestinal epithelial cells and myeloid cells. Immunobiology 2015; 220: 1161-1169.
Cavaglieri CR, Nishiyama A, Fernandes LC et al. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sci 2003; 73: 1683-1690.
Marzocco S, Fazeli G, Di Micco L et al. Supplementation of short-chain fatty acid, sodium propionate, in patients on maintenance-“beneficial effects on inflammatory parameters and gut-derived uremic toxins”-A Pilot Study (PLAN Study). J Clin Med 2018; 7: 315.
De Vadder F, Kovatcheva-Datchary P, Goncalves D et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014; 156: 84-96.
Pingitore A, Chambers ES, Hill T et al. The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes Obes Metab 2017; 19: 257-265.
Wright RS, Anderson JW, Bridges SR. Propionate inhibits hepatocyte lipid synthesis. Proc Soc Exp Biol Med 1990; 195: 26-29.
Morfeld M, Kirchberger I, Bullinger M. SF-36 Fragebogen zum Gesundheitszustand: Deutsche Version des Short Form-36 Health Survey. 2011.
Kleinman AJ, Sivanandham R, Pandrea I, Chougnet CA, Apetrei C. Regulatory T cells as potential targets for HIV cure research. Front Immunol 2018; 9: 1.
Rocco J, Mellors JW, Macatangay BJC. Regulatory T cells: the ultimate HIV reservoir? J Virus Erad 2018; 4: 209-214.
Tran T-A, de Goër de Herve M-G, Hendel-Chavez H et al. Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One 2008; 3: e3305.
Kendrick SFW, O'Boyle G, Mann J et al. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology 2010; 51: 1988-1997.
Park J, Goergen CJ, HogenEsch H, Kim CH. chronically elevated levels of short-chain fatty acids induce T cell-mediated ureteritis and hydronephrosis. J Immunol 2016; 196: 2388-2400.
Vujkovic-Cvijin I, Sortino O, Verheij E et al. HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases. Nat Commun 2020; 11: 1-15.
Lozupone CA, Li M, Campbell TB et al. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe 2013; 14: 329-339.
Mutlu EA, Keshavarzian A, Losurdo J et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014; 10: e1003829.
Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two-way street. Aids 2016; 30: 2737-2751.
Zilberman-Schapira G, Zmora N, Itav S et al. The gut microbiome in human immunodeficiency virus infection. BMC Med 2016; 14: 83.
Rocafort M, Noguera-Julian M, Rivera J et al. Evolution of the gut microbiome following acute HIV-1 infection. Microbiome 2019; 7: 1-17.
González-Hernández LA, Ruiz-Briseño MR, Sánchez-Reyes K et al. Alterations in bacterial communities, SCFA and biomarkers in an elderly HIV-positive and HIV-negative population in western Mexico. BMC Infect Dis 2019; 19.
Qing Y, Xie H, Su C et al. Gut microbiome, short-chain fatty acids, and mucosa injury in young adults with human immunodeficiency virus infection. Dig Dis Sci 2019; 64: 1830-1843.
Vandeputte D, Falony G, Vieira-Silva S et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut 2016; 65: 57-62.
Vázquez-Castellanos JF, Serrano-Villar S, Latorre A et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol 2015; 8: 760-772.
Cook RR, Fulcher JA, Tobin NH et al. Combined effects of HIV and obesity on the gastrointestinal microbiome of young men who have sex with men. HIV Med 2020; 21: 365-377.
Dillon SM, Abdo MH, Wilson MP et al. A unique gut microbiome-physical function axis exists in older people with HIV: an exploratory study. AIDS Res Hum Retroviruses 2021; 37: 542-550.
Tuddenham S, Koay WL, Sears C. HIV, sexual orientation, and gut microbiome interactions. Dig Dis Sci 2020; 65: 800-817.
Noguera-Julian M, Rocafort M, Guillén Y et al. Gut microbiota linked to sexual preference and HIV infection. EBioMedicine 2016; 5: 135-146.
Armstrong AJS, Shaffer M, Nusbacher NM et al. An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men. bioRxiv 1-16 2018. https://doi.org/10.1101/424291
Dubourg G, Lagier J-C, Hue S et al. Gut microbiota associated with HIV infection is significantly enriched in bacteria tolerant to oxygen. BMJ Open Gastroenterol 2016; 3: 1-9.
Gootenberg DB, Paer JM, Luevano JM, Kwon DS. HIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammation. Curr Opin Infect Dis 2017; 30: 31-43.
Liu RT, Rowan-Nash AD, Sheehan AE et al. Reductions in anti-inflammatory gut bacteria are associated with depression in a sample of young adults. Brain Behav Immun 2020; 88: 308-324.
Chambers ES, Viardot A, Psichas A et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 2015; 64: 1744-1754.
Psichas A, Sleeth ML, Murphy KG et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes 2015; 39: 424-429.
Jiao A, Yu B, He J et al. Short chain fatty acids could prevent fat deposition in pigs: via regulating related hormones and genes. Food Funct 2020; 11: 1845-1855.
Byrne CS, Chambers ES, Morrison DJ, Frost G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int J Obes 2015; 39: 1331-1338.